Literature DB >> 8045977

Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men.

C J Bagatell1, J R Heiman, A M Matsumoto, J E Rivier, W J Bremner.   

Abstract

In addition to their use as replacement therapy for hypogonadal males, androgens, particularly testosterone (T), are being explored as potential hormonal male contraceptive agents, alone or in combination with other compounds. Androgens have regulatory effects on a variety of physiological systems in addition to gonadotropin secretion and spermatogenesis. Therefore, as hormonal contraceptive regiments that alter serum T levels are explored, it is important to evaluate their effects on these aspects of normal male physiology. The effects of exogenous T on suppression of spermatogenesis in 19 healthy men were recently compared, using a T dosage of 200 mg im/week for 20 weeks. Before treatment, the men were evaluated during a 3-month pretreatment period, and after treatment, they were followed for 4-6 months or until their sperm counts normalized. Because of the lack of information regarding the effects of exogenous T on nonreproductive physiology, we examined the effects of high-dose T on plasma lipids, calcium metabolism, and sexual behavior in our subjects. Mean serum T and estradiol levels increased significantly during the treatment period. Plasma high-density lipoprotein (HDL) cholesterol levels decreased significantly within the first month and remained suppressed during the duration of T administration. At the end of the treatment period, mean plasma HDL cholesterol had decreased by 13 +/- 2% (P < 0.05); plasma levels of HDL2, HDL3, and apoprotein AI also decreased significantly; mean levels of low density lipoprotein cholesterol and triglycerides were unchanged. After 1 month of the recovery period, plasma HDL levels had returned to the baseline range. Serum calcium levels decreased slightly during treatment; this decrease was statistically significant. Urinary calcium excretion did not change. Mean levels of serum intact PTH increased by 84 +/- 17% (P < 0.05) during T administration; in contrast, 25-hydroxyvitamin D levels decreased by 16 +/- 4% (P < 0.05), and 1,25-dihydroxyvitamin D levels did not change significantly. All markers of calcium metabolism returned to baseline during the posttreatment period. Little change was found in self-reported sexual and aggressive behaviors during the study. There was a trend toward increased arousal and spontaneous erections during T administration, but this did not reach statistical significance. Frequency of sexual intercourse, masturbation, and kissing and fondling did not change, nor was the subjects' satisfaction in their relationships affected by T administration. Mean body weight increased by 4.0 +/- 0.5 kg. Approximately half the men noted mild acne. Body weight and acne symptoms returned to baseline during the recovery period.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8045977     DOI: 10.1210/jcem.79.2.8045977

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

1.  Correlation between serum total testosterone and the AMS and IIEF questionnaires in patients with erectile dysfunction with testosterone deficiency syndrome.

Authors:  Jae Kang; Byeong Kuk Ham; Mi Mi Oh; Je Jong Kim; Du Geon Moon
Journal:  Korean J Urol       Date:  2011-06-17

Review 2.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

Review 3.  Testosterone therapy in men: clinical and pharmacological perspectives.

Authors:  A Gambineri; R Pasquali
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 4.256

Review 4.  Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update.

Authors:  M S Bahrke; C E Yesalis; J E Wright
Journal:  Sports Med       Date:  1996-12       Impact factor: 11.136

5.  Testosterone and the metabolic syndrome.

Authors:  Vakkat Muraleedharan; T Hugh Jones
Journal:  Ther Adv Endocrinol Metab       Date:  2010-10       Impact factor: 3.565

6.  Testosterone and insulin resistance in the metabolic syndrome and T2DM in men.

Authors:  Preethi M Rao; Daniel M Kelly; T Hugh Jones
Journal:  Nat Rev Endocrinol       Date:  2013-06-25       Impact factor: 43.330

7.  Mood Symptoms in Steroid Users: The Unexamined Role of Concurrent Stimulant Use.

Authors:  Pilar M Sanjuan; James L Langenbucher; Tom Hildebrandt
Journal:  J Subst Use       Date:  2015-09-18

Review 8.  Illicit anabolic-androgenic steroid use.

Authors:  Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Horm Behav       Date:  2009-09-18       Impact factor: 3.587

Review 9.  Male contraception.

Authors:  John K Amory
Journal:  Fertil Steril       Date:  2016-09-24       Impact factor: 7.329

Review 10.  Progress and prospects in male hormonal contraception.

Authors:  John K Amory
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-06       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.